Technology
Health
Biotechnology

Translate Bio

$8.96
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.96 (-9.68%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell Translate Bio and other stocks, options, ETFs, and crypto commission-free!

About

Translate Bio, Inc. engages in the research and development of therapeutic drugs. It focuses on developing medicines to treat diseases caused by protein or gene dysfunction. Read More Its lead product candidates include MRT5005 for the treatment of cystic fibrosis; and for the treatment of ornithine transcarbamylase deficiency. The company was founded by Arthur M. Krieg and Jeannie T. Lee in 2011 and is headquartered in Lexington, MA.

Employees
81
Headquarters
Lexington, Massachusetts
Founded
2011
Market Cap
404.47M
Price-Earnings Ratio
Dividend Yield
Average Volume
141.06K
High Today
$9.96
Low Today
$8.96
Open Price
$9.93
Volume
43.14K
52 Week High
$16.60
52 Week Low
$4.81

Collections

Technology
Health
Biotechnology
Research And Development
2018 IPO
US
North America

News

Markets InsiderMar 4

Translate Bio to Present at the 39th Annual Cowen and Company Healthcare Conference

LEXINGTON, Mass., March 04, 2019 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction, today announced that Ronald Renaud, chief executive officer, will present a corporate overview at the 39th Annual Cowen and Company Healthcare Conference on Monday, March 11, 2019, at 12:00 p.m. ET at the Boston Marriott Copley Place. A live webca...

897
MarketBeatFeb 13

Stock Price, News, & Analysis for Translate Bio

Translate Bio, Inc., a messenger RNA therapeutics company, engages in developing medicines to treat diseases caused by protein or gene dysfunction. It is developing MRT5005 that is in Phase I/II clinical trial for the treatment of cystic fibrosis; and MRT5201 for the treatment of ornithine transcarbamylase deficiency. It has strategic alliances with Sanofi Pasteur. The company was formerly known as RaNA Therapeutics, Inc. and changed its name to Translate Bio, Inc. in June 2017. Translate Bio, Inc. was foun...

628

Earnings

Q2 2018
Q3 2018
Q4 2018
Estimated
Actual
Available Mar 21, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.